Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • Data Privacy
  • Français
  • my CNW 
    • Login
    • Register
  • Client Login 
    • Online Member Centre
    • Next Gen Communications Cloud
    • Cision Communications Cloud®
  • Sign Up
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
Advanced Search
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Canadian Federal Government
      • Canadian Municipal Government
      • Canadian Provincial Government
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

  • Advanced Search
  • Overview
  • Multichannel Amplification
  • Monitoring
  • Distribution
  • Multimedia
  • Guaranteed Paid Placement
  • AI Tools
  • IR
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Worldwide Offices
  • Hamburger menu
  • Cision Canada
  • Send a Release
  • FR
    • Phone

    • 877-269-7890 from 8 AM - 10 PM ET

    • ALL CONTACT INFO
    • Contact Cision

      877-269-7890
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • Overview
  • Multichannel Amplification
  • Monitoring
  • Distribution
  • Multimedia
  • Guaranteed Paid Placement
  • AI Tools
  • IR
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR

Health Canada Approves DARZALEX® (daratumumab) for Newly Diagnosed Patients with Multiple Myeloma who are Transplant Ineligible Français


News provided by

Janssen Inc.

Dec 17, 2018, 08:04 ET

Share this article

Share toX

Share this article

Share toX

DARZALEX® combination therapy significantly reduced the risk of disease progression or death compared to a preferred regimen alone.1,2

TORONTO, Dec. 17, 2018 /CNW/ - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that Health Canada has approved DARZALEX® (daratumumab), in combination with bortezomib, melphalan and prednisone (VMP), for the treatment of patients newly diagnosed with multiple myeloma who are ineligible for autologous stem cell transplantation.3 DARZALEX® is the first monoclonal antibody to be approved for newly diagnosed patients in Canada.

Multiple myeloma is an incurable blood cancer that occurs when malignant plasma cells grow uncontrollably in the bone marrow.4,5    The disease can be very complex to treat as most patients relapse or become resistant to standard therapies, but with increasing research and treatment advances, the outlook for patients is improving.6,7,8 Eight Canadians are diagnosed each day, with an average age of diagnosis in the mid-sixties.9 Work is ongoing with both public and private insurers to determine how DARZALEX® can be accessible for newly diagnosed, transplant ineligible patients.

"This daratumumab combination regimen for newly diagnosed patients who don't qualify for a transplant can result in lower risk of disease progression and higher rates of response," says Dr. Darrell White, Hematologist, Queen Elizabeth II Health Sciences Centre. "The data supports this regimen as an effective new option for this patient population."

This marks the third indication for DARZALEX®. In June 2016, Health Canada approved DARZALEX® for those with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), or who are refractory to both a PI and an IMiD (meaning they didn't respond to or relapsed while on those treatments).10  In April 2017, the medication was approved for use earlier in the disease - for patients who have received at least one prior therapy. For these patients, DARZALEX® is used in combination with either lenalidomide and dexamethasone, or with bortezomib and dexamethasone.11 DARZALEX® is now publicly funded in the province of Québec for the treatment of patients with multiple myeloma who have received at least one prior therapy.

The Health Canada approval of DARZALEX® in combination with VMP is supported by data from the randomized, open-label, multicenter Phase 3 ALCYONE (MMY3007) study, published in the New England Journal of Medicine. The combination of DARZALEX® with VMP reduced the risk of disease progression or death by 50 per cent, compared to treatment with VMP alone (Hazard Ratio [HR] = 0.50; 95 per cent confidence interval (CI) [0.38-0.65], p<0.0001).12 The median progression-free survival (PFS) for DARZALEX® in combination with VMP had not yet been reached, compared to a median PFS of 18.1 months for patients who received VMP alone.13

Treatment with DARZALEX® in combination with VMP significantly improved overall response rates (90.9vs. 73.9%) compared to VMP alone.14 Additionally, measures of stringent complete response (18 vs. 7%), complete response (24.6 vs.17.4%) and very good partial response (28.6 vs. 25.3%) all showed marked improvement.15 Patients receiving DARZALEX® in combination with VMP achieved a more than three-fold increase in the minimal residual disease (MRD) negativity rate (21.1 vs. 6.2%) compared to those who received VMP alone.16

In the study, the most frequently reported Treatment Emergent Adverse Events (TEAEs) (≥20%) in the DARZALEX®-VMP (D-VMP) arm were: infusion-related reactions, neutropenia, thrombocytopenia, anemia, upper respiratory tract infection, pyrexia, diarrhea, nausea, and peripheral sensory neuropathy.17 The overall incidence of serious TEAEs was 41.6% in the D-VMP arm and 32.5% in the VMP arm.18 Serious TEAEs (≥2%) with at least a 2% higher incidence in the  D-VMP arm compared to the VMP arm included infections (23.1% vs 11.9%), including pneumonia (D-VMP 10.1% vs VMP 3.1%).19 Infusion-related reactions were reported in 27.7% of patients in the D-VMP group.20 Treatment-emergent hematology laboratory abnormalities for D-VMP vs. VMP were lymphopenia (85% vs. 83%), neutropenia (86% vs. 87%), thrombocytopenia (88% vs. 88%) and anemia (47% vs. 50%).21 The warnings and precautions for DARZALEX® include infusion reactions, infections, interference with indirect antiglobulin test, interference with determination of complete response, neutropenia, thrombocytopenia and infections.22

About Multiple Myeloma
Multiple myeloma is the most common plasma cell cancer23 and is characterized by an excess proliferation of plasma cells.24 In Canada, there were an estimated 2,900 new cases in 2017 and an estimated 1,450 deaths associated with the disease.25 While some patients with multiple myeloma have no symptoms in the early stages, most patients are diagnosed due to symptoms that can include bone disease or pain, anemia, calcium elevation, and kidney problems.26

About DARZALEX® (daratumumab)
DARZALEX® is the first CD38-directed monoclonal antibody (mAb) approved to treat multiple myeloma. It binds to CD38, a surface protein highly expressed across multiple myeloma cells.27 DARZALEX® induces tumor cell death through cell lysis via multiple immune-mediated mechanisms of action, including complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).28 DARZALEX® has also demonstrated immunomodulatory effects such as increasing CD4+ and CD8+ T-cells counts, which may contribute to clinical response. 29 Additional studies are ongoing to evaluate DARZALEX® in combination with standard of care regimens for newly diagnosed patients who are eligible and ineligible for autologous stem cell transplant (ASCT).

In August 2012, Janssen Biotech, Inc. and Genmab A/S entered a worldwide agreement, which granted Janssen an exclusive license to develop, manufacture and commercialize DARZALEX®. Janssen Inc. commercializes DARZALEX® in Canada. For full Prescribing Information and more information about DARZALEX®, please visit www.janssen.com/canada.  

About the Janssen Pharmaceutical Companies of Johnson & Johnson
At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science.

We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at www.janssen.com/canada. Follow us at @JanssenCanada. Janssen Inc. is part of the Janssen Pharmaceutical Companies of Johnson & Johnson.

*Dr. Darrell White was not compensated for any media work. He has been compensated as a consultant.

References:
_____________________________
1 [DARZALEX™ Product Monograph, Janssen Inc., November 27, 2018]
2 NCBI. "Bortezomib, Melphalan, and Prednisone (VMP) Regiment for Multiple Myeloma," Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4321425/. Accessed November 2018.
3 [DARZALEX™ Product Monograph, Janssen Inc., November 27, 2018]
4 Kumar, SK et al. Leukemia. 2012 Jan; 26(1):149-57.; American Cancer Society. "Multiple Myeloma Overview." Available at: http://www.cancer.org/cancer/multiplemyeloma/detailedguide/multiple-myeloma-what-is-multiple-myeloma. Accessed November 2018.
5 American Cancer Society. "Multiple Myeloma Overview." Available at: http://www.cancer.org/cancer/multiplemyeloma/detailedguide/multiple-myeloma-what-is-multiple-myeloma. Accessed November 2018.
6 Kumar, SK et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516–20.
7 Turesson, I et al. Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. J Clin Oncol 2010;28: 830–34.
8 Myeloma Canada. "About Myeloma" https://www.myelomacanada.ca/en/about-multiple-myeloma/what-is-myeloma. Accessed November 2018.
9 Myeloma Canada. "About Myeloma" https://www.myelomacanada.ca/en/about-multiple-myeloma/what-is-myeloma. Accessed November 2018.
10 [DARZALEX™ Product Monograph, Janssen Inc., November 27, 2018]
11 [DARZALEX™ Product Monograph, Janssen Inc., November 27, 2018]
12 [DARZALEX™ Product Monograph, Janssen Inc., November 27, 2018]
13 [DARZALEX™ Product Monograph, Janssen Inc., November 27, 2018]
14 [DARZALEX™ Product Monograph, Janssen Inc., November 27, 2018]
15 [DARZALEX™ Product Monograph, Janssen Inc., November 27, 2018]
16 [DARZALEX™ Product Monograph, Janssen Inc., November 27, 2018]
17 [DARZALEX™ Product Monograph, Janssen Inc., November 27, 2018]
18 [DARZALEX™ Product Monograph, Janssen Inc., November 27, 2018]
19 [DARZALEX™ Product Monograph, Janssen Inc., November 27, 2018]
20 [DARZALEX™ Product Monograph, Janssen Inc., November 27, 2018]
21 [DARZALEX™ Product Monograph, Janssen Inc., November 27, 2018]
22 [DARZALEX™ Product Monograph, Janssen Inc., November 27, 2018]
23 Canadian Cancer Society. "Types of Multiple Myeloma," Available at: http://www.cancer.ca/en/cancer-information/cancer-type/multiple-myeloma/multiple-myeloma/types-of-multiple-myeloma/?region=on. Accessed November 2018.
24 American Cancer Society. "Multiple Myeloma Overview," Available at: http://www.cancer.net/cancer-types/multiple-myeloma/overview. Accessed November 2018.
25 Canadian Cancer Society. "Canadian Cancer Statistics 2018." Available at: http://www.cancer.ca/~/media/cancer.ca/CW/cancer%20information/cancer%20101/Canadian%20cancer%20statistics/Canadian-Cancer-Statistics-2018-EN.pdf?la=en. Accessed November 2018.
26 Canadian Cancer Society. "Signs and Symptoms of Multiple Myeloma," Available at: http://www.cancer.ca/en/cancer-information/cancer-type/multiple-myeloma/signs-and-symptoms/?region=on.Accessed November 2018.
27 [DARZALEX™ Product Monograph, Janssen Inc., November 27, 2018]
28 [DARZALEX™ Product Monograph, Janssen Inc., November 27, 2018]
29 [DARZALEX™ Product Monograph, Janssen Inc., November 27, 2018]

SOURCE Janssen Inc.

Media Contact: Janssen Inc., Jennifer McCormack, Office: (416) 382-5121; Investor Contact: Lesley Fishman, Office: (732) 524-3922

Modal title

Organization Profile

Janssen Inc.

    Also from this source

  • Health Canada authorizes LAZCLUZE® (lazertinib) in combination with RYBREVANT® (amivantamab) as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer

  • Johnson & Johnson champions first-ever Canadian consensus paper identifying critical gaps in psoriasis care for patients with skin of colour

  • RYBREVANT® plus chemotherapy approved in Canada as first and only targeted treatment to reduce risk of disease progression or death by more than half in second-line EGFR-mutated advanced lung cancer

Contact Cision

  • 866-245-2317
    from 8 AM - 10 PM ET
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media

Products

  • Cision Communications Cloud®
  • Media Monitoring
  • Content Distribution
  • Multimedia Distribution
  • Measurement & Analytics
  • Investor Relations

About

  • About Cision Canada
  • About Cision
  • Media Partners
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Online Member Centre
  • Next Gen Communications Cloud
  • Cision Communications Cloud®
  • my CNW

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Centre
  • Next Gen Communications Cloud
  • Cision Communications Cloud
  • my CNW
877-269-7890
from 8 AM - 10 PM ET
  • Terms of Use
  • Information Security Policy
  • Site Map
  • Cookie Settings
  • Accessibility Statement
Copyright © 2025 CNW Group Ltd. All Rights Reserved. A Cision company.